Celebrating One Year of Spot On CML

Celebrating One Year of Spot On CML

The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.

These tests are critically important because a confirmed diagnosis is required for a patient to begin receiving free treatment through our donation programs – and access to treatment is access to life.

We extend our deepest thanks to the dedicated team at Fred Hutch and the hundreds of physicians and nurses around the world who work tirelessly to support their patients. Thanks to your efforts, we not only met but exceeded our initial goal – testing one new patient per day for an entire year.

Here’s how the patient numbers break down by country:

  • Bhutan – 5
  • Cambodia – 2
  • Cote d’Ivoire – 10
  • East Timor – 3
  • Fiji – 5
  • Honduras – 40
  • Kenya – 7
  • Mexico – 30
  • Mongolia – 21
  • Nepal – 95
  • Niger – 18
  • Nigeria – 10
  • Philippines – 17
  • Tajikistan – 50
  • Uganda – 58

About Spot On CML 

Launched in 2017, Spot On CML is a groundbreaking collaboration between The Max Foundation and Fred Hutchinson Cancer Research Center (Fred Hutch) to increase access to testing for chronic myeloid leukemia (CML) patients in under-resourced countries. The initiative utilizes a special process developed by Fred Hutch researcher and The Max Foundation board member Dr. Jerry Radich. In it, paper test cards are spotted with dried blood samples and mailed to Fred Hutch from all over the world, where researchers perform testing on the samples free-of-charge.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation & Esperantra Forge a Deeper Collaboration to Benefit Leukemia Patients in Peru

    The Max Foundation & Esperantra Forge a Deeper Collaboration to Benefit Leukemia Patients in Peru

    The Max Foundation and partner NGO Esperantra are pleased to announce they have signed a new MOU that will help patients in Peru gain access to treatment.

  • The Max Foundation Releases Video from Global Experience

    The Max Foundation Releases Video from Global Experience

    Watch The Max Foundation’s video from Max Global Experience Uganda. The Max Global Experience Uganda was a fundraising and engagement opportunity for patient leaders, industry partners, and Max team members to come together to expand access to cancer treatment in Africa. The global experience included an all-day symposium, a visit to the Uganda Cancer Institute, and a “last mile” walk along the Nile in solidarity with patients across Africa.

  • The Max Foundation Partners with Leading Pharmaceutical Company to Advance Health Equity Through Expanded CML Treatment Access for Patients in 36 Low-Middle-Income Countries

    Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12, 2022 – The Max Foundation (Max), a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally,….